Release date: 2015-05-04
“Internet + medicalâ€, which represents the future trend, will attract many pharmaceutical companies to join in. In this incentive competition, traditional companies will be eliminated, and those pharmaceutical companies that can successfully transform and dare to adopt new technologies will be able to stay ahead and win. victory.
Which technologies and applications with Internet genes are most strategic for pharmaceutical companies? The Arterial Network uses a global survey by PricewaterhouseCoopers to illustrate. According to the PwC report, in the next five years, global pharmaceutical companies will face industrial transformation, from the traditional pharmaceutical production to the high-tech, new technology Internet medical field. Future hotspots include social media marketing, data mining analysis, privacy security, mobile APP technology, open APP technology, network transmission products and services and other Internet technologies (below).
The New York-based medical health accelerator StartUp Health also has relevant research and analysis. The results show that the top three investment giants in the Internet medical field since 2010 are Merck's Global Health Innovation Fund, Blue Cross Blue Shield Insurance Company and Qualcomm Investment, representing medicine. The three major industries of business, health insurance and mobile technology. It is estimated that in the next five to seven years, the total investment in medical and health IT (HIT) in 22 countries will reach 500 billion US dollars.
Major pharmaceutical giants are actively pursuing ways and means of leveraging “Internet Plus†in a multi-dimensional manner, including self-developing mobile app applications with multiple functions and strategic meanings, and working closely with other digital healthcare entrepreneurial teams, including self-investment. Or participate in accelerated entrepreneurship projects in the field of incubation. Self-construction or cooperation with counterpart accelerators, early exploration of market-oriented and pioneering entrepreneurial projects has become an important way for pharmaceutical giants to grasp the opportunities of science and technology for the first time. The Arterial Network Internet Medical Research Institute has compiled detailed information on the multinational pharmaceutical giant Top10 self-built or participated in the cooperative medical technology entrepreneurial accelerator.
The situation of major pharmaceutical giants deploying accelerators in the Internet medical field is shown in the following table.
12 pharmaceutical giant Internet medical accelerator events
Pfizer Pfrizer
As the world's largest pharmaceutical company, Pfrizer established Pfizer Ventures in 2004, focusing on the world's leading technology companies, injecting $50 million annually into medical innovation companies in the form of private investment. It invested in the rare disease drug accelerator Cydan and entered into a strategic partnership with the Blueprint Health accelerator to become a mentor to guide innovative companies. At the end of 2006, Pfizer announced the establishment of an incubator at the La Jolla Research Institute to help the development of budding biotech companies. Since 2007, Dr. Polinsky has founded the Pfizer incubator TPI and served as CEO. TPI has provided 10 million US dollars per year for companies in the incubator to support the development of new drugs and to solve the problem of expiration of several internal drug patents. Additional benefits of TPI include the provision of Pfrizer's expert advice and amenities, although Pfrizer has exclusive access, but allows third-party valuations and retains copyright for researchers.
In addition, Pfrizer has invested $10 million in the Scripps Research Institute and is a project sponsor of the well-known New York Digital Medical Accelerator (NYDHA), which funds production operations.
In April 2015, Pfrizer teamed up with the American AARP to launch a pilot program for building mobile health applications and devices, hoping to meet the needs of the elderly.
Pfrizer also actively expands cooperation with companies in special regions and special fields, such as sponsoring cooperation with Israel to help solve mobile medical problems, and participating in the development of an IOS game for the treatment of Almerz disease.
Pfizer executive Ms. Mayer once said that Pfizer initially invested in equity and soon discovered that this model is not conducive to the integration of new technologies. Therefore, in order to learn from cooperation, Pfrizer is now focusing on investing in promising quality companies. Fresh information technology is also available.
It is worth mentioning that in January 2015, Pfizer China organized an Internet medical competition for the domestic market, and explored a high-quality entrepreneurial team to seek valuable and in-depth cooperation.
Bayer HealthCare Bayer
In 2013, Bayer supported several Internet medical innovation companies and built a partnership with Healthbox. The Healthbox Accelerator in Florida also works with Blue Shield Insurance, which supports each project for 16 weeks, investing $50,000 in seed money for a promising company, and swapping a 7% stake.
In 2014, Bayer finally established its own accelerator. VentureBeat reports that Bayer HealthCare is the first pharmaceutical company to build its own accelerator. "New software, hardware, technology, and new companies that improve the results of treatment and contribute to human health" are Bayer's support goals.
In 2013, Bayer HealthCare selected five new companies in Berlin to become pioneers and launched the crowdsourcing project Grants4Apps. In 2014, the project was expanded into an accelerator. A total of 70 companies were selected and five were selected. The selected companies can Received a 3.5-month support period, obtained initial funding of $65,000, and sold 10% of the shares. The first batch of company products are based on sensors, mobile tracking devices, and health care applications.
5 company product introduction:
1. Cortium: A wearable sensor that uses electrodes to track physiological conditions such as ECG scans, heart rate, respiration rate, body surface temperature, sleep analysis, physical activity levels, body position, and exercise.
2. PharmaAssistant: Developed the SmartBottles APP to provide visual and audible alerts to alert patients to medication.
3. FabUlyze: Wearable devices that use nanosensors to sense the user's breathing and determine their physical condition.
4.Parica: A non-contact detection system is being developed to analyze vital signs, and a problem will warn the doctor.
5. CardiMoni: Develop applications to detect heart rate and irregular rhythms.
Baxter Baxter
Baxter has more than 80 years of experience in the healthcare industry, with sales of $16.7 billion in 2014 and approximately 65,500 employees. The company treats medical experts and patients with complex and difficult diseases such as hemophilia, immune, infectious, kidney, trauma and other chronic and acute diseases. As a global diversified healthcare company, Baxter not only manufactures medical devices, but also has advanced pharmaceutical and production technology students, serving the world.
In addition, as an investor, Baxter worked with the New York Digital Medical Accelerator (NYDHA) to provide financial and intellectual support for promising new technology products and treatment options.
Merk Pharmaceuticals
In 2010, the world's top 500 German Merck Company established the Global Medical Innovation Fund (Merk GHI) to use the medical and health ecosystem accumulated over many years to work with medical investment institutions to support innovative companies and provide solutions for solving medical problems. Merck is also a major investor in the accelerator Rock Health, supporting at least 15 startups by 2013. These 15 include Adflow kiosk (free test heart rate, blood pressure); Humedica (test weight, analytical data); Prophecy (modeling prediction and drug research and development).
In 2012, Merk's innovation team, Merck Medical Information and Innovation (M2i2), was established to explore the development model and prospects of Internet healthcare with healthcare practitioners, EMR providers and startups.
On January 7, 2013, Patient Safe Solutions, one of its portfolio companies, announced a $20 million Series C round, led by Merck. The software allows hospital nurses to collect up-to-date bedside patient information, check drug prescriptions, and quickly coordinate with other clients.
Merk GHI plans to invest $500 million in research and development of medical technology for companies worldwide. For the emerging and emerging medical technology companies, Merck uses its global resources to provide a strong support for small businesses and is a solid backing.
Accelerator Tigerlabs Health is located in the heart of a large pharmaceutical company in central New Jersey. It provides startups with $20,000 in seed funding, facilities for mentoring, professional seminars, and joint office space. Tigerlabs emphasizes that its outstanding advantage is close to the "pharmaceutical industry giants", such as Merck, Johnson & Johnson, Bristol Myers-Squibb, Novartis, and Novo Nordisk, etc., to facilitate the communication of emerging technologies.
On April 17, 2013, TigerLabs announced that Merk GHI and the New York-Presbyterian will be the first initial partners.
In addition, Merck is also an investor in the New York Digital Medical Accelerator (NYDHA).
Novartis Nonovts
Novartis AG in Switzerland has a leading position in innovative drug development, eye protection, genetic medicine, preventive vaccines, and over-the-counter medicines. In 2014, it partnered with the European Incubator Startup Training Camp to become a mentor and first pilot customer of the training camp. The Startup Camp is a global accelerator with projects in Amsterdam, Berlin and Copenhagen. For each project, select 10 potential companies from among 500 applicants. The start-up company received a start-up capital of 15,000 euros, a free office space, a 3-month support period and a sponsorship partnership worth 300,000 euros. According to statistics, 85% of the training camp teams are operating well, and 70% are ready for a new batch of financing.
In January 2015, San Diego's telecom giant Qualcomm plans to re-engage with Novartis to build 100 million sponsorship funds for mobile medical companies. At the same time, Novartis also uses Qualcomm's 2net platform to evaluate patients with chronic lung diseases using mobile devices. Health status and help manage the disease. Therefore, Novartis believes that this cooperation is of great significance and can create more breakthrough new application technologies for the society.
Sanofi Sanofi
In October 2011, PositiveID announced the official release of the iglucose diabetes management system sponsored by the Sanofi and AMDA associations.
In June 2012, Cincinnati Internet Medical Accelerator Innov8 announced the launch of a new accelerator with Sanofi and other strategic partners. The Innov8 Medical Accelerator program has a three-month support period and trades 6% of the shares, providing $20,000 in start-up funding. The first batch of short-listed companies are:
1.CCM link, developed a CHARTS application that can remind you of life-health.
2. Chronic Care Solutions, which changes the habits of people with diabetes through digital media and social games to make life healthier.
3. I Feel Great APP, educating patients to save on medical expenses and paying attention to health and safety.
4. Business Solutions (Intec Solutions) IT solutions for handling system access requests.
5.MedaCheck, develop a complete set of hardware and software to solve the serious drug compliance problem.
6. Better appointment (Betterpointment), can quickly and easily use machine learning technology to help patients make appointments.
7. Innovative applications, dedicated to helping people to realize their potential, providing long-term, effective, easy-to-use solutions to overcome difficulties in life.
GlaxoSmithKline GSK
In 2012, GSK developed the UK's first innovative biomedical science park, Stevenage Bioscience Catalyst (SBC), which is strategically located at 95,000 square feet and provides resources such as laboratories, office space, cyberspace and stand-alone equipment. A total of £38 million was contributed by six partners, including GSK and the Wellcome Trust.
On March 13, 2012, Infosys Co., Ltd. announced that it has cooperated with GSK to cooperate in the global medical consumption and health care field to jointly optimize online operation channels.
In August 2014, the UK public health department, GSK and BUPA discussed the Be He@lthy mobile project. The project is targeted at combating chronic non-communicable diseases in underdeveloped and developing countries.
In November 2014, GSK announced that the most successful APP was “My Asthmaâ€, so GSK is a small test in the direction of mobile medical tools. There are 6 projects. In order to better develop, GSK will work with data startup Medidata. Work with sensor manufacturers Vital Connet and AcriGraph to evaluate the practical role of wearable devices in clinical care.
Roche Roche
In February 2013, Roche acquired Genetech, which is also launching a new mobile app in the biopharmaceutical sector. According to TabTimes, Genetech has more than 60 apps in the App Store. Genentech GeneTech is also a sponsor of the New York Internet Medical Accelerator. The company's main business is the use of human genetic information to discover, research, produce and commercialize drugs for the diagnosis and treatment of serious, life-threatening diseases. Look at the future with a developmental perspective, meet the needs of users, and continue to innovate in new areas.
In May 2013, Roche and the California Institute of Quantum Biology announced an alliance to provide strategic guidance and financial support for early bio-startups.
The New York Digital Medical Accelerator (NYDHA) primarily supports early-stage Internet healthcare companies with a focus on advanced areas such as care coordination, patient management, predictive analytics, and workflow optimization. In March 2014, Roche became one of the many sponsors.
AstraZeneca AstraZeneca
In December 2014, OneStart, the world's largest bioscience and health care business accelerator, announced that it will cooperate with J&J, GSK, Roche, AstraZeneca and a number of institutional companies in 2015 for treatment, diagnostics, software, medical equipment, research tools, etc. The field provides sponsorship support. The finalists will be free to enter the experimental space in May 2015 and receive a funding award: 100,000 euros for the European team and $150,000 for the US company.
DigitasLBi and AstraZeneca have teamed up to create the Internet Innovation Group DIG, which develops the most advanced mobile devices and presents the most innovative medical ideas, such as the first generation of DoctorsNotes, which helps medical professionals buy, discover and share medical papers.
Johnson & Johnson J&J
In 2013, Johnson & Johnson Innovation provided $50,000 in awards for two companies in the Almerz and Cognitive Disorder areas, along with offices and laboratories in San Francisco, and startups Johnson & Johnson California Innovation Center's team of expert instructors. Johnson & Johnson Innovation is made up of four accelerators, the first in San Diego, the second in Boston, the third in South San Francisco, the fourth in San Francisco, and the last one planned to land in Houston in 2016. pause.
In October 2014, J&J formed a new team called Jensen Medical Innovation (JHI), which is deeply involved in the field of Internet medicine innovation and created the Care4Today product, reminding users to take medicine on time and donate money for charity activities. JHI's California Innovation Center is also comprised of four divisions, the remaining three being located in Boston, Shanghai, and London. .
Abbott Labs Abbott Labs
In 2013, The Iron Yard, an Internet medical accelerator in Southern California, was formed. The official website stated that “only companies that support software, or a combination of hardware and software, do not prefer medical equipment or basic research in life sciences.â€
The selected company will receive a $20,000 seed round fund to exchange 6% of the shares, in addition to financial support, office space, staff quarters and so on. Although the project only supports 3 months, the company can use the office space throughout the year.
Eli Lilly
In 2014, WellDoc, the earliest and best-known mobile healthcare company focused on diabetes management, worked with Eli Lilly, Lil, Merck and Sanofi to develop mobile apps.
In July 2014, accelerator company Accelerator Corporation received $51.1 million in funding to help new biotech companies in New York and Seattle provide research opportunities from a variety of investors, including Eli Lilly, J&J and other well-known companies.
Source: Arterial Network Internet Medical Research Institute
Roasted Pumpkin Seeds,Baking Pumpkin Seeds,Cooking Pumpkin Seeds,Toasted Pumpkin Seeds
Wuyuan county dafeng oil food co.,ltd , https://www.dafengfood.com.cn